Anthera Pharmaceuticals Inc  

(Public, NASDAQ:ANTH)   Watch this stock  
Find more results for anth
1.55
+0.06 (4.03%)
Dec 15 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.46 - 1.58
52 week 1.20 - 17.04
Open 1.48
Vol / Avg. 243,954.00/543,240.00
Mkt cap 21.47M
P/E     -
Div/yield     -
EPS -5.42
Shares 13.85M
Beta 2.71
Inst. own 18%
Feb 26, 2018
Q4 2017 Anthera Pharmaceuticals Inc Earnings Release (Estimated) - 9:30AM EST - Add to calendar
Jan 5, 2018
Anthera Pharmaceuticals Inc Extraordinary Shareholders Meeting - 2:00PM EST - Add to calendar
Nov 6, 2017
Q3 2017 Anthera Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -38291.72%
Operating margin - -39432.41%
EBITD margin - -39248.96%
Return on average assets -221.19% -155.10%
Return on average equity -1194.68% -305.37%
Employees 33 -
CDP Score - -

Address

25801 Industrial Blvd Ste B
HAYWARD, CA 94545-2223
United States - Map
+1-510-8565600 (Phone)
+1-510-8565597 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Anthera Pharmaceuticals, Inc. (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod. Sollpura is a non-porcine investigational Pancreatic Enzyme Replacement Therapy (PERT) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (EPI), often seen in patients with cystic fibrosis and other conditions. Blisibimod targets B-cell activating factor (BAFF), which has been shown to be elevated in a range of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), or lupus, Immunoglobulin A nephropathy (IgA) nephropathy, lupus nephritis and others.

Officers and directors

Paul F. Truex Executive Chairman of the Board
Bio & Compensation  - Reuters
Craig Thompson President, Chief Executive Officer, Chief Operating Officer, Director
Age: 50
Bio & Compensation  - Reuters
May Liu Senior Vice President - Finance and Administration, Principal Accounting Officer
Age: 39
Bio & Compensation  - Reuters
William R. Shanahan Jr. M.D. J.D. Chief Medical Officer
Age: 68
Bio & Compensation  - Reuters
Brent Furse Director
Age: 47
Bio & Compensation  - Reuters
Christopher S. Henney Ph.D. Independent Director
Age: 76
Bio & Compensation  - Reuters
Brian R. Mueller Independent Director
Age: 43
Bio & Compensation  - Reuters
Philip T Sager Independent Director
Age: 59
Bio & Compensation  - Reuters
David E. Thompson Independent Director
Age: 67
Bio & Compensation  - Reuters